Gatifloxacin versus ceftriaxone for uncomplicated enteric fever in Nepal: an open-label, two-centre, randomized controlled trial
Background Because treatment with third-generation cephalosporins is associated with slow clinical improvement and high relapse burden for enteric fever, whereas the fluoroquinolone gatifloxacin is associated with rapid fever clearance and low relapse burden, we postulated that gatifloxacin would b...
Сохранить в:
Главные авторы: | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Формат: | Technical Report |
Язык: | en_US |
Опубликовано: |
Lancet Infect Dis 2016
2016
|
Предметы: | |
Online-ссылка: | http://103.69.126.140:8080/handle/123456789/818 |
Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|
Итог: | Background Because treatment with third-generation cephalosporins is associated with slow clinical improvement and high relapse burden for enteric fever, whereas the fluoroquinolone gatifloxacin is associated with rapid fever clearance and low relapse burden, we postulated that gatifloxacin would be superior to the cephalosporin ceftriaxone in treating enteric fever. |
---|